Novo Nordisk’s stock has dropped dramatically by 58% since its peak in December 2024, falling from about $116 to around $48. This steep decline shows the strong selling pressure the company is experiencing, mainly due to a persistent downward trendline that is blocking any attempts at recovery. A crucial support level has formed at $48-49, called the “Line In The Sand.” This area offers a chance for a potential turnaround. For investors hoping to see some stability, this level is important. If Novo Nordisk can hold this support, it could see rallies pushing the stock up to $52-54. However, overcoming the ongoing downward trend will be tough. If the stock goes below $48, it may drop to the $42-44 range. Volume will be key in this situation; it will help determine whether there is a genuine capitulation or a false break. Novo Nordisk is navigating mixed feelings in the market due to the sensitivity of its sector to drug trials and regulatory changes. Traders are closely watching to see if $48 will be the lowest point for the stock or if more declines are on the way. The current path of the stock presents classic risk-reward opportunities for investors. We are closely monitoring Novo Nordisk as it tests the important $48 support level following a steep drop from near $116 in December 2024. The options market is showing high uncertainty, with implied volatility reaching levels not seen since Eli Lilly’s competitive data came out in mid-2025. This indicates that traders are anticipating a significant price movement soon. For those hoping for a bounce back from this oversold condition, buying short-dated call options could provide substantial leverage. With short interest reported by S&P Global at over 15% of the float, any good news could trigger a strong short squeeze, pushing the stock toward the initial $52 resistance. This is a high-risk strategy based on the idea that the stock is now fundamentally undervalued after the panic selling. However, if the stock decisively breaks below $48 with heavy volume, the bearish case would gain significant strength. Considering their Q3 2025 earnings showed the first sequential decline in Wegovy prescriptions, further declines to the $42-$44 range seem likely. In this case, buying put options or creating bear call spreads could be effective strategies. Given the binary nature of this situation, it’s wise to wait for confirmation before making significant commitments. Another approach is to trade the volatility directly, possibly using a long straddle, which would benefit from a large price movement in either direction. This strategy is suitable for uncertain times like this, where a significant move seems likely but the direction is unclear. We’ve seen similar situations in the past where a former market leader faced strong competition and saw its valuation reset. Looking back at Gilead Sciences in the mid-2010s, after they lost their dominance in the hepatitis C market, shows these downtrends can last a long time. Right now, all attention is on that “Line In The Sand” at $48, which will determine the next major move for Novo Nordisk.

here to set up a live account on VT Markets now